TP53 and carcinoma of esophagus: While developed as a p53 stabilizing agent, it has emerged that TP53’s mutation status alone is not a satisfactory biomarker for APR-246/PRIMA-1 sensitivity, e.g., in Ewing sarcoma and esophagus carcinoma models [54,55].